Editas Medicine, Inc. EDIT

How is it a scam...also I think we have over tested $30 mark next stop $40 imho

I recall that article and think the market is telling us that EDIT will be first with proof of concept. The study is literally in the same building with the FDA in Mass.. regardless to regulations, rules and laws people will be people and people talk. It happens at every level across all leadership. This is not a buy the rumor type of situation it is a mega trend in the making. Biotech, AI and 5G related services will replace FANG as the best of breed imo.

Go edit!

I do not see how gene base editing is more effective/efficient. Beam says it’s like using a pencil to erase and correct each letter rather then scissors to cut out and replace a sequence of letters. I would think that cutting out and replacing the section would make more sense as you know the new GTAC sequence is corrected entirely. Only time will tell. This is what makes biotech such an exciting place to invest.

Two things for sure and one for certain Blackrock and Vanguard are in the top ten of major holders here and at every large cap brand you can think of. To me that is a good sign for this small cap. Look it up they are the top ten in Amzn, AAPL, Fb, dis, McD, msft, Tesla...the list goes on. I think we are all in a good place Longs for the long term and shorty who knows how to play the game,

It would be great if the free up of the rights from Abbvie was to pursue better relationships and opportunities from major suitors. Maybe that is why they are thrilled. Smart money knows that biotech is next megatrend. The inflows last quarter exceeded all of 2019. That type of momentum does not just stop. Do not get caught picking up pennies in front of that freight train!!

Hmmmm only time will tell. More positive news is imminent based on CC. Chief Scientist sounds confident in there approach to CRISPR 09-12. I cannot wait to see where this ends up over the next 12/mo. I expect it to be biggest winner in the portfolio. Long
$EDIT, $HIMX, $GBTC, $ETHE, $DDD, $SPRO,$STM looking to add some $BLDP in the mix soon. Do your own DD and GLTA!

Another CRISPR-based test, developed by Sherlock Biosciences and CRISPR pioneer Feng Zhang, received an emergency use authorization (EUA) from the Food and Drug Administration in May — the agency's first for any CRISPR-based technology. (Mammoth has since received an EUA for another CRISPR-based test.)

Merger smerger RJ is with the program. Abbvie is more interested in remedies not cures. Editas is much better candidate on its own with BMY. They will realize the mistake they made once they are superseded by this little gem.

Agreed the more important thing is the progress of EDIT-101, IND for Sickle cell and funds look good to profitability